Johnson & Johnson (JNJ) Income Statement Analysis

See more : Daheng New Epoch Technology Inc. (600288.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Johnson & Johnson (JNJ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson & Johnson, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Neo-Concept International Group Holdings Limited (NCI) Income Statement Analysis – Financial Results
Onde S.A. (OND.WA) Income Statement Analysis – Financial Results
Lionsgate Studios Corp. (LION) Income Statement Analysis – Financial Results
Otonomo Technologies Ltd. (OTMO) Income Statement Analysis – Financial Results
Covenant Logistics Group, Inc. (CVLG) Income Statement Analysis – Financial Results

Johnson & Johnson (JNJ)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.jnj.com

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	85.16B	79.99B	78.74B	82.58B	82.06B	81.58B	76.45B	71.89B	70.07B	74.33B	71.31B	67.22B	65.03B	61.59B	61.90B	63.75B	61.10B	53.32B	50.51B	47.35B	41.86B	36.30B	33.00B	29.14B	27.47B	23.66B	22.63B	21.62B	18.84B	15.73B	14.14B	13.75B	12.45B	11.23B	9.76B	9.00B	8.01B	7.00B	6.42B
Cost of Revenue	26.55B	24.60B	23.40B	28.43B	27.56B	27.09B	25.35B	21.69B	21.54B	22.75B	22.34B	21.66B	20.36B	18.79B	18.45B	18.51B	17.75B	15.06B	13.95B	13.42B	12.18B	10.45B	9.54B	7.35B	7.00B	6.19B	6.09B	6.01B	5.38B	4.58B	4.17B	4.12B	3.71B	3.46B	3.07B	2.90B	2.60B	2.35B	2.34B
Gross Profit	58.61B	55.39B	55.34B	54.16B	54.50B	54.49B	51.10B	50.21B	48.54B	51.59B	48.97B	45.57B	44.67B	42.80B	43.45B	45.24B	43.34B	38.27B	36.56B	33.93B	29.69B	25.85B	23.47B	21.79B	20.47B	17.47B	16.54B	15.61B	13.46B	11.16B	9.96B	9.64B	8.74B	7.77B	6.69B	6.10B	5.41B	4.65B	4.08B
Gross Profit Ratio	68.82%	69.25%	70.28%	65.58%	66.42%	66.79%	66.84%	69.84%	69.27%	69.40%	68.67%	67.78%	68.69%	69.49%	70.20%	70.96%	70.95%	71.76%	72.38%	71.65%	70.91%	71.22%	71.11%	74.79%	74.53%	73.83%	73.11%	72.21%	71.46%	70.92%	70.48%	70.06%	70.19%	69.17%	68.58%	67.77%	67.52%	66.37%	63.50%
Research & Development	15.05B	14.14B	14.28B	12.34B	11.36B	10.78B	10.55B	9.10B	9.05B	8.49B	8.18B	7.67B	7.55B	6.84B	7.17B	7.76B	7.68B	7.13B	6.31B	5.20B	4.68B	3.96B	3.59B	2.93B	2.60B	2.27B	2.14B	0.00	0.00	1.28B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	20.11B	19.05B	20.12B	22.08B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	20.11B	19.05B	20.12B	22.08B	22.18B	22.54B	21.42B	19.95B	21.20B	21.95B	21.83B	20.87B	20.97B	19.42B	19.80B	21.49B	20.45B	17.43B	16.88B	15.86B	14.13B	12.22B	11.99B	10.88B	10.50B	8.91B	8.72B	10.30B	9.10B	6.35B	6.95B	6.80B	6.08B	5.30B	4.62B	4.30B	3.85B	3.39B	2.99B
Other Expenses	0.00	500.00M	-526.00M	-2.90B	-2.53B	-1.41B	-183.00M	-484.00M	2.06B	70.00M	-2.50B	-1.63B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	35.56B	33.18B	34.40B	34.42B	33.53B	33.32B	31.97B	29.04B	30.25B	30.45B	30.01B	28.53B	28.52B	26.27B	26.97B	29.25B	28.13B	24.56B	23.19B	21.06B	18.82B	16.17B	15.58B	15.32B	14.55B	12.42B	11.92B	11.31B	9.95B	8.35B	7.57B	7.36B	6.57B	5.78B	5.03B	4.70B	4.20B	3.66B	3.24B
Cost & Expenses	61.81B	57.78B	57.80B	62.85B	61.09B	60.41B	57.33B	50.73B	51.79B	53.19B	52.36B	50.19B	48.88B	45.06B	45.42B	47.76B	45.88B	39.62B	37.14B	34.49B	30.99B	26.62B	25.12B	22.66B	21.55B	18.61B	18.01B	17.32B	15.33B	12.93B	11.74B	11.48B	10.28B	9.24B	8.10B	7.60B	6.80B	6.02B	5.58B
Interest Income	1.26B	490.00M	53.00M	111.00M	357.00M	611.00M	385.00M	368.00M	128.00M	67.00M	74.00M	64.00M	91.00M	107.00M	90.00M	361.00M	452.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	772.00M	276.00M	183.00M	201.00M	318.00M	1.01B	934.00M	726.00M	552.00M	533.00M	482.00M	532.00M	571.00M	348.00M	451.00M	435.00M	296.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	7.49B	6.97B	7.39B	7.23B	7.01B	6.93B	5.64B	3.75B	3.75B	3.90B	4.10B	3.67B	3.16B	2.94B	2.77B	2.83B	2.78B	2.18B	2.09B	2.12B	1.87B	1.66B	1.61B	1.52B	1.44B	1.25B	1.07B	1.01B	857.00M	724.00M	617.00M	560.00M	493.00M	474.00M	414.00M	391.00M	356.00M	275.20M	250.50M
EBITDA	23.73B	27.17B	30.93B	27.50B	28.27B	28.10B	24.54B	24.92B	22.12B	25.03B	23.16B	17.96B	16.05B	20.35B	18.96B	20.20B	16.36B	15.77B	15.61B	15.02B	13.27B	11.82B	9.78B	8.08B	7.59B	6.96B	5.62B	5.46B	4.42B	3.58B	2.93B	2.78B	2.65B	2.63B	2.08B	1.70B	1.47B	1.79B	985.40M
EBITDA Ratio	27.86%	37.71%	35.38%	29.27%	26.96%	27.64%	25.95%	30.16%	27.15%	28.68%	27.40%	27.07%	29.93%	26.84%	27.51%	27.84%	32.86%	29.58%	30.91%	31.72%	31.71%	32.57%	29.63%	27.73%	27.64%	29.41%	24.81%	25.24%	23.45%	22.72%	20.73%	20.24%	21.32%	23.45%	21.33%	18.88%	18.29%	25.50%	15.35%
Operating Income	23.41B	23.19B	20.47B	16.95B	15.12B	15.62B	14.20B	17.93B	15.28B	17.42B	15.43B	14.53B	16.31B	13.59B	14.26B	14.92B	17.30B	13.60B	13.52B	12.90B	11.40B	10.16B	8.18B	6.57B	6.15B	5.71B	4.55B	4.45B	3.56B	2.85B	2.31B	2.22B	2.16B	2.16B	1.67B	1.31B	1.11B	1.51B	734.90M
Operating Income Ratio	27.49%	28.99%	26.00%	20.52%	18.42%	19.15%	18.57%	24.94%	21.80%	23.44%	21.64%	21.61%	25.08%	22.06%	23.03%	23.40%	28.31%	25.50%	26.76%	27.24%	27.24%	27.99%	24.77%	22.53%	22.38%	24.14%	20.10%	20.57%	18.90%	18.12%	16.37%	16.16%	17.36%	19.23%	17.09%	14.53%	13.84%	21.57%	11.44%
Total Other Income/Expenses	-8.35B	-2.85B	-1.77B	-3.24B	2.21B	2.38B	-1.22B	-1.09B	907.00M	-574.00M	38.00M	-3.26B	-3.79B	420.00M	-908.00M	760.00M	-1.93B	990.00M	137.00M	482.00M	-563.00M	-387.00M	-277.00M	303.00M	-108.00M	-846.00M	-46.00M	-270.00M	-194.00M	-126.00M	-62.00M	-70.00M	-126.00M	-369.00M	-147.00M	-8.00M	-16.00M	-592.80M	164.30M
Income Before Tax	15.06B	19.36B	19.18B	16.50B	17.33B	18.00B	17.67B	19.80B	19.20B	20.56B	15.47B	13.78B	12.36B	16.95B	15.76B	16.93B	13.28B	14.59B	13.66B	12.84B	10.31B	9.29B	7.90B	6.62B	5.75B	4.27B	4.58B	4.03B	3.32B	2.68B	2.33B	2.21B	2.04B	1.62B	1.51B	1.40B	1.19B	390.80M	899.20M
Income Before Tax Ratio	17.69%	24.20%	24.36%	19.98%	21.12%	22.06%	23.12%	27.55%	27.39%	27.66%	21.69%	20.49%	19.01%	27.52%	25.45%	26.56%	21.74%	27.36%	27.03%	27.11%	24.62%	25.60%	23.93%	22.73%	20.94%	18.05%	20.22%	18.65%	17.60%	17.04%	16.49%	16.05%	16.37%	14.45%	15.52%	15.51%	14.89%	5.58%	14.00%
Income Tax Expense	1.74B	2.99B	1.38B	1.78B	2.21B	2.70B	16.37B	3.26B	3.79B	4.24B	1.64B	3.26B	2.69B	3.61B	3.49B	3.98B	2.71B	3.53B	3.25B	4.33B	3.11B	2.69B	2.23B	1.82B	1.59B	1.21B	1.27B	1.15B	914.00M	675.00M	545.00M	582.00M	577.00M	480.00M	432.00M	422.00M	360.00M	61.30M	285.50M
Net Income	35.15B	17.94B	20.88B	14.71B	15.12B	15.30B	1.30B	16.54B	15.41B	16.32B	13.83B	10.85B	9.67B	13.33B	12.27B	12.95B	10.58B	11.05B	10.41B	8.51B	7.20B	6.60B	5.67B	4.80B	4.17B	3.06B	3.30B	2.89B	2.40B	2.01B	1.79B	1.03B	1.46B	1.14B	1.08B	974.00M	833.00M	329.50M	613.70M
Net Income Ratio	41.28%	22.43%	26.52%	17.82%	18.42%	18.75%	1.70%	23.01%	21.99%	21.96%	19.40%	16.14%	14.87%	21.65%	19.82%	20.31%	17.31%	20.73%	20.61%	17.97%	17.19%	18.17%	17.17%	16.47%	15.17%	12.93%	14.60%	13.35%	12.75%	12.75%	12.64%	7.49%	11.74%	10.18%	11.09%	10.82%	10.40%	4.71%	9.56%
EPS	13.88	6.86	7.93	5.59	5.74	5.75	0.48	6.08	5.57	5.86	4.90	3.91	3.54	4.86	4.45	4.67	3.67	3.76	3.38	2.75	2.42	2.20	1.87	1.65	1.43	1.08	1.24	1.09	0.93	0.78	0.69	0.17	0.55	0.43	0.41	0.36	0.31	0.12	0.21
EPS Diluted	13.73	6.73	7.81	5.51	5.63	5.61	0.47	5.93	5.48	5.70	4.81	3.86	3.49	4.78	4.40	4.57	3.63	3.73	3.35	2.74	2.29	2.16	1.84	1.61	1.39	1.06	1.21	1.09	0.93	0.78	0.68	0.16	0.54	0.43	0.40	0.35	0.31	0.12	0.21
Weighted Avg Shares Out	2.53B	2.61B	2.63B	2.63B	2.63B	2.66B	2.68B	2.71B	2.76B	2.78B	2.82B	2.78B	2.72B	2.74B	2.76B	2.81B	2.88B	2.94B	2.98B	2.97B	2.97B	3.00B	3.03B	2.99B	2.99B	2.78B	2.67B	2.66B	2.58B	2.57B	2.61B	2.63B	2.66B	2.66B	2.67B	2.74B	2.73B	2.75B	2.92B
Weighted Avg Shares Out (Dil)	2.56B	2.66B	2.67B	2.67B	2.68B	2.73B	2.75B	2.79B	2.81B	2.86B	2.88B	2.81B	2.78B	2.79B	2.79B	2.84B	2.91B	2.96B	3.00B	2.99B	3.14B	3.05B	3.08B	3.10B	3.07B	2.83B	2.74B	2.73B	2.58B	2.61B	2.63B	2.63B	2.71B	2.69B	2.71B	2.78B	2.73B	2.75B	2.92B

Johnson & Johnson Preferred Financing, Inc. Implements 2iG's PFC Insight

October 23, 2024globenewswire.com

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- 2iG Solutions, Inc. (2iG or 2iG Solutions), provider of leading-edge data analytics and artificial intelligence (AI) reporting software, is pleased to announce that South Carolina-based premium finance company Johnson & Johnson Preferred Financing...

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

October 23, 2024zacks.com

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year

October 19, 2024fool.com

Investors looking for dividend stocks at reasonable valuations have come to the right place.

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

October 19, 2024fool.com

These companies' longtime shareholders have generally been rewarded.

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

October 19, 2024seekingalpha.com

J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and MedTech, despite ongoing challenges. The company updated its full-year guidance, showing optimism despite headwinds like talc litigation and STELARA generic competition, maintaining...